Celularity jumps after cancer drug gets FDA's Fast Track tag

Celularity

27/12/2021 14:12

** Shares of the biotech co  CELU.O  climb ~11% to $5.22
premarket — set for their biggest jump in more than three
months, if gains hold
    ** U.S. FDA grants Fast Track Designation to co's drug
candidate, CYNK-001, being developed for the treatment of acute
myeloid leukemia (AML)  urn:newsml:reuters.com:*:nGNX9LzxBj 
    ** AML is a blood cancer that disrupts the production of
normal blood cells in the bone marrow
    ** The Fast Track Designation is given by the FDA to
facilitate the development, and expedite the review of drugs to
treat serious conditions and fill an unmet medical need 
    ** Up to Friday's close, stock had fallen 57.27% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))